### Table of Contents

**February 1, 2015 • Volume 21 • Number 3**

**Clinical Cancer Research**

**SPECIAL FEATURES**

**CCR 20th Anniversary Commentary**

493  
**CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma**  
Susan J. Knox and Ronald Levy

**CCR Translations**

495  
**Novel Targets in Head and Neck Cancer: Should We Be Optimistic?**  
Gabriel S. Krigsfeld and Christine H. Chung  
See related article, p. 632

**Molecular Pathways**

498  
**Molecular Pathways: Autophagy in Cancer—A Matter of Timing and Context**  
Michelle Cicchini, Vassiliki Karantza, and Bing Xia

505  
**Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells**  
Verline Justilien and Alan P. Fields

**Special Report**

514  
**Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology**  

**Review**

526  
**HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma**  
Netanya I. Pollock and Jennifer R. Grandis

### CANCER THERAPY: CLINICAL

534  
**Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans**  

544  
**Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck**  
Han Sang Kim, Hyoong Ju Kwon, Inkyung Jung, Mi Ran Yun, Myung-Ju Ahn, Byung Woong Kang, Jong-Mu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon Uk Park, Se-Hoon Lee, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Jin Hee Sohn, Bomi Kim, Nak-Jung Kwon, Hwan Jung Yun, Min Goo Lee, Ji Hyun Lee, Tae-Min Kim, Hye Ryun Kim, Joo Hang Kim, Soonmyung Pyak, and Byoung Chul Cho

553  
**First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma**  
Jordi Rodon, Michael A. Carducci, Juan M Sepulveda-Sánchez, Analia Azaro, Emiliano Calvo, Joan Seoane, Irene Braña, Elisabet Sicart, Ivelina Georgieva, Ann L. Cleverly, N. Sokalingum Pillay, Durisala Desaiha, Shawn T. Estrem, Luis Paz-Ares, Matthias Hohlholf, Jaishri Blakeley, Michael M. Lahn, and Jose Baselga

### PERSONALIZED MEDICINE AND IMAGING

561  
**The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma**  
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>652</td>
<td>Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer</td>
<td>Francisco J. Candido-dos-Reis, Honglin Song, Ellen L. Goode, Julie M. Cunningham, Brooke L. Fridley, Melissa C. Larson, Kathryn Alseop, Ed Dicks, Patricia Harrington, Susan J. Ramus, Anna de Fazio, Gillian Mitchell, Sian Fereday, Kelly L. Bolton, Charlie Gourley, Caroline Michie, Beth Karlan, Jenny Lester, Christine Walsh, Ilana Cass, Håkan Olsson, Martin Gore, Javier J. Benitez, Maria J. Garcia, Irene Andrulis, Anna Marie Mulligan, Gord Glendon, Ignacio Blanco, Conxi Lazaro, Alice S. Whitemore, Valerie McGuire, Weiva Sieh, Marco Montagnana, Elisa Alducci, Siegal Sadetzki, Angela Chetrit, Ava Kwong, Susanne K. Kjaer, Allan Jensen, Estrid Hugdall, Susan Neuhausen, Robert Nussbaum, Mary Daly, Mark H. Greene, Phuong L. Mai, Jennifer T. Loud, Kirsten Moysich, Amanda E. Toland, Diether Lambrechts, Steve Ellis, Debra Frost, James D. Brenton, Marc Tischkowitz, Douglas F. Easton, Antonis Antoniou, for EMBRACE, Georgia Chenevix-Trench, for kConFab Investigators, Simon A. Gayther, David Bowtell, for The Australian Ovarian Cancer Study Group, and Paul D.P. Pharoah</td>
</tr>
</tbody>
</table>

**LETTERS TO THE EDITOR**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>658</td>
<td>DNA Repair Mutations and Outcomes in Ovarian Cancer—Letter</td>
<td>Robert A. Soslow</td>
</tr>
<tr>
<td>659</td>
<td>DNA Repair Mutations and Outcomes in Ovarian Cancer—Response</td>
<td>Elizabeth M. Swisher, Barbara M. Norquist, Kathryn P. Pennington, Mara H. Rendi, and Rochelle L. Garcia</td>
</tr>
</tbody>
</table>

**CORRECTIONS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>660</td>
<td>Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer</td>
<td></td>
</tr>
<tr>
<td>661</td>
<td>Correction: HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer</td>
<td></td>
</tr>
<tr>
<td>662</td>
<td>Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors</td>
<td></td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

The cover shows NFκB translocation in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Immunocytochemistry staining shows NFκB (p65) translocation (red is nucleus; green is NFκB; and yellow is overlay [translocation]) in the nucleus of tumor-infiltrating lymphocytes expanded with IL-2 and an anti-4-1BB antibody. For details, see the article by Chacon and colleagues on page 611 of this issue.